News | Radiation Therapy | July 11, 2016

New study finds higher rate of larynx preservation with the addition of monoclonal antibody cetuximab than with radiotherapy alone

July 11, 2016 — A new study assed the rates of laryngeal preservation and laryngectomy-free survival in patients receiving the monoclonal antibody cetuximab and radiation therapy (CRT) or radiation therapy alone. The study, conducted by James A. Bonner, M.D., of the University of Alabama at Birmingham and colleagues, was published online by JAMA Otolaryngology-Head & Neck Surgery.

Historically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy. Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation. After the realization that many patients could avoid total laryngectomy with the use of primary radiotherapy, several combination chemoradiotherapy strategies were introduced for patients with laryngeal or hypopharyngeal cancers.

This study consisted of a secondary subgroup analysis of patients who were enrolled in a randomized, phase 3 study from 73 centers in the United States and 14 other countries. Of the 424 patients included in the trial, 168 treated patients with cancer of the larynx or hypopharynx were included in the subgroup analysis (90 in the CRT group and 78 in the radiotherapy alone group). The rates of laryngeal preservation at two years were 88 percent for CRT versus 86 percent for radiotherapy alone. This study was not powered to assess organ preservation. Median overall survival was 27 versus 21 months for the CRT and radiotherapy alone groups, respectively. There was a 4 percent and 8.9 percent absolute improvement in laryngectomy-free survival at two and three years, respectively, for CRT versus radiotherapy alone. No differences between treatments were reported regarding overall quality of life, need for a feeding tube or speech.

"The higher rate of laryngeal preservation that was achieved with the use of CRT compared with radiotherapy alone was encouraging," the authors wrote. "These results need to be interpreted in the context of a retrospective subset analysis with limited sample size."

"This treatment approach warrants further evaluation in larger populations to fully assess the potential value of cetuximab or other molecular targeting agents to augment laryngeal preservation rates," they concluded.

For more information: www.archotol.jamanetwork.com


Related Content

News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Population Health

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Time April 04, 2024
arrow
News | Radiation Oncology

April 2, 2024 — In a 10-center study, microwave ablation offered progression free survival rates and fewer complications ...

Time April 02, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
Subscribe Now